The Drug Committee of Ministry of Health, Labour and Welfare in Japan has accepted a 2-year extension of market exclusivity of Lexapro®
· A two-year extension of the reexamination period by the Japanese Ministry of Health, Labour and Welfare (MHLW) has been discussed and accepted in the First Committee on Drug of MHLW · The acceptance is based on the fact that clinical development on pediatrics will be conducted in order to meet the unmet needs of depression in pediatrics · Japanese anti-depressant market was valued at approximately DKK 9 billion in 2017 Valby, Denmark, 27 April 2018 - H. Lundbeck A/S (Lundbeck) today announced that Lexapro® (escitalopram oxalate), which is distributed by Mochida Pharmaceutical Co.,